Success stories in structure-based drug design

Periodicum Biologorum

Volumn 100, Issue SUPPL. 2, 1998, Pages 93-98

  Klebe, Gerhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2142641658     PISSN: 00315362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ALLEN F A, KENNARD O, TAYLOR R 1983 Systematic Analysis of Structural Data as a Research Technique in Organic Chemistry. Acc Chem Res 16: 146-153
2. BEDDELL C R, GOODFORD P J, NORRINGTON F E 1976 Compounds Designed to Fit a Site of Known Structure in Human Hemoglobin. Br J Phamac 57: 201-209
3. BÖHM H J, KLEBE G 1996 What Can We Learn From Molecular Recognition in Protein-Ligand Complexes for the Design of New Drugs? Angew Chem Int Ed Engl 35: 2588-2614
4. BÖHM H J, KLEBE G, KUBINYI H 1996 Wirkstoffdesign. Spektrum Akad. Verlag, Heidelberg.
5. CUSHMAN D W, CHEUNG H S, SABO E F, ONDETTI M A 1977 Design of Potent Competitive Inhibitors of Angiotensin-Converting Enzyme. Carboxyalkanoyl and Mercaptoalkanoyl Amino Acids. Biochemistiy 16: 5484-5491
6. GOODFORD P 1984 Drug Design by the Method of Receptor Fit. J Med Chem 27: 557-564
7. GOODFORD P 1985 A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules 28: 849-857
8. HOL W G J 1986 Protein Crystallography and Computer Graphics - Toward National Drug Design. Angew Chem Int Ed Engl 25: 767-778
9. JONES T R, VARNEY M D, WEBBER S E et al. 1996 Structure-Based Design of Lipophilic Quinazoline Inhibitors of Thymidylate Synthase. J Med Chem 39: 904-917
10. LAM P Y S, JADHAV P K, EYERMANN C J et al. 1994 Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 263: 380-384
11. MONTFORT W R, PERRY K M, FAUMAN E B, FINER MOORE J S, MALEY G F, HARDY F, MARLEY F, STROUD R M 1990 Structure, Multiple Site Binding, and Segmental Accomodation in Thymidylate Synthase on Binding UMP and Anti-Folate. Biochemistry 29: 6964-6977
12. NAVIA M A, MURCKO M A 1992 Use of Structural Information in Drug Design. Current Opinion in Structural Biology 2: 202-210
13. OBST U 1997 De Novo-Design und Synthese Neuartiger, Nichtpeptidischer Thrombin-Inhibitoren. Diss. ETH Nr. 12037, Zürich, Switzerland.
14. OBST U, GRAMLICH V, DEDERICH F, WEBER L, BANNER D W 1995 Design of Novel, Nonpeptidic Thrombin Inhibitors and Structure of a Thrombin-Inhibitor Complex. Angew Chem Int Ed Engl 34: 1739-1742
15. REICH S H, WEBBER S E 1993 Structure-Based Drug Design (SBDD): Every Structure Tells a Story. Persp Drug Discov Design 1: 371-390
16. REICH S H, FUHRY M A, NGUYEN D et al. 1992 Design and Synthesis of Novel 6,7-Imidazotetrahydroquinoline Inhibitors of Thymidylate Synthase Using Iterative Protein Crystal Structure Analysis. J Med Chem 35: 847-858
17. WALKINSHAW M D 1992 Protein Targets for Structure-based Drug Design. Med Res Rev 12: 317-372
18. WEST M L, FAIRLIE D P 1995 A Test for Drug-Design Methodologies. Trends Pharm Sci 16: 67-74
19. WEBBER S E, BLECKMAN T M, ATTARD J et al. 1993 Design of Thymidylate Synthase Inhibitors Using Protein Crystal Structures: The Synthesis and Biological Evaluation of a Novel Class of 5-Substituted Quinazolinones. J Med Chem 36: 733-746